Last reviewed · How we verify
NCT07249697: RFPNEC
Risk Factors for Poor Prognosis in Neonatal Necrotizing Enterocolitis
trial testing Observational retrospective cohort study in Necrotizing Enterocolitis in 118 participants. Completed in 30 June 2025.
30 June 2025
Quick facts
| Lead sponsor | Guangzhou Women and Children's Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 118 |
| Start date | 1 July 2017 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Observational retrospective cohort study
Conditions studied
- Necrotizing Enterocolitis — all drugs for Necrotizing Enterocolitis →
Sponsor
Guangzhou Women and Children's Medical Center
Who can join
Adults 1 Day to 3 Months, any sex, with Necrotizing Enterocolitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective study led by Guangzhou Women and Children's Medical Center, focusing on newborns diagnosed with necrotizing enterocolitis (NEC)-a serious gastrointestinal disease that threatens newborns' lives-between January 2017 and December 2022. Purpose of the study: NEC can lead to severe conditions like bowel perforation or even death, and it's hard for doctors to spot high-risk babies early with current tools. This study aims to analyze the babies' clinical information (e.g., birth weight, symptoms like belly swelling or bloody stools), blood test results (e.g., lactate levels, white blood cell counts), and organ function scores (nSOFA scores) to find indicators that can predict whether NEC will get worse or cause death. Questions the study tries to answer: Can combining metabolic indicators (like lactate), blood test parameters, and organ function scores better predict if a newborn with NEC will develop perforated NEC (a more severe form where the bowel has holes) or die during hospitalization? Are these combined indicators more reliable than single indicators alone? Study hypothesis: We guess that integrating metabolic markers (such as lactate), blood routine parameters, and nSOFA scores will be more accurate than using any single indicator to predict the progression of NEC and the risk of death in affected newborns.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07249697
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational retrospective cohort study
Trials testing the same drug.
- NCT07207915 — Analysis of Integrated Clinical, Laboratory and Prognostic Data of Neonates With Necrotizing Enterocolitis · completed
Other recruiting trials for Necrotizing Enterocolitis
Currently open trials in the same condition.
- NCT06681129 — Study of Normal Intestinal Development and Disease in Premature and Term Neonates · recruiting
- NCT06672913 — Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study · NA · recruiting
- NCT06908239 — Milk Temperature Control and Necrotizing Enterocolitis Risk in Extremely Preterm Infants · NA · active not recruiting
- NCT06032676 — Qualitative Study of Surgeons With Prospective Patient Follow-up · recruiting
- NCT05272579 — PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants · EARLY_PHASE1 · recruiting
Other Guangzhou Women and Children's Medical Center trials
Trials by the same sponsor.
- NCT07190001 — YOLT-204 in Patients With Hemoglobinopathies · EARLY_PHASE1 · not yet recruiting
- NCT06904729 — Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children · Phase 3 · recruiting
- NCT06948994 — A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Di · Phase 1, PHASE2 · not yet recruiting
- NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
- NCT06731205 — Long-term Renal Prognosis of Neonatal Acute Kidney Injury · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07249697 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Women and Children's Medical Center
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07249697.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing